AC
Arena Capital Advisors, LLC- CA
13F filer · CIK 0001833078Reported Jul 23, 2026
Net buyer this quarter
13F portfolio value$208MU.S. long equity reported on 13F
Positions111 new · 0 closed
Net flow last quarter+$14.5MBuys minus sells
Top 10 positions weight16.9%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Jul 23, 202611 positions | |||||
| $16.4M | 7.87% | Not reported | New | Q2 2026 | |
| $9.7M | 4.67% | 0.36% | -17.3% | Q3 2025 | |
| $5.12M | 2.46% | 0.06% | Not reported | Q4 2021 | |
| $2.39M | 1.15% | 0.94% | Not reported | Q3 2025 | |
| $1.06M | 0.51% | 0.08% | +14.1% | Q4 2022 | |
| $296K | 0.14% | 0.00% | Not reported | Q1 2026 | |
| $260K | 0.13% | 0.02% | Not reported | Q2 2021 | |
| $17K | 0.01% | Not reported | Not reported | Q3 2024 | |
| $6.49K | 0.00% | Not reported | Not reported | Q2 2021 | |
| LPLIMNWLiminatus Pharma, Inc. | $2.19K | 0.00% | Not reported | Not reported | Q2 2025 |
| $382 | 0.00% | Not reported | Not reported | Q4 2023 | |
| Q1 2026Reported May 4, 202610 positions | |||||
| $9.59M | 4.80% | 0.44% | -12.8% | Q3 2025 | |
| $4.32M | 2.16% | 0.06% | Not reported | Q4 2021 | |
| $1.04M | 0.52% | 0.07% | Not reported | Q4 2022 | |
| $727K | 0.36% | 0.94% | Not reported | Q3 2025 | |
| $279K | 0.14% | 0.00% | New | Q1 2026 | |
| $161K | 0.08% | 0.02% | Not reported | Q2 2021 | |
| $23.8K | 0.01% | Not reported | Not reported | Q3 2024 | |
| $4.04K | 0.00% | Not reported | Not reported | Q2 2021 | |
| LPLIMNWLiminatus Pharma, Inc. | $1.17K | 0.00% | Not reported | Not reported | Q2 2025 |
| $511 | 0.00% | Not reported | Not reported | Q4 2023 | |
| Q4 2025Reported Feb 4, 202613 positions | |||||
| $8.22M | 4.97% | 0.50% | Not reported | Q3 2025 | |
| $3.05M | 1.84% | 0.06% | Not reported | Q4 2021 | |
| $930K | 0.56% | 0.01% | New | Q4 2025 | |
| $914K | 0.55% | 0.07% | Not reported | Q4 2022 | |
| $578K | 0.35% | 0.94% | Not reported | Q3 2025 | |
| $240K | 0.14% | 0.02% | Not reported | Q2 2021 | |
| $237K | 0.14% | 0.00% | Not reported | Q2 2025 | |
| $153K | 0.09% | 0.01% | New | Q4 2025 | |
| $38.8K | 0.02% | Not reported | New | Q4 2025 | |
| $17.2K | 0.01% | Not reported | -49.2% | Q3 2024 | |
| $4.57K | 0.00% | Not reported | Not reported | Q2 2021 | |
| LPLIMNWLiminatus Pharma, Inc. | $1.02K | 0.00% | Not reported | Not reported | Q2 2025 |
| $546 | 0.00% | Not reported | Not reported | Q4 2023 | |
| Q3 2025Reported Nov 13, 202516 positions | |||||
| $34.9M | 14.49% | 1.69% | -37.5% | Q3 2023 | |
| $7.18M | 2.98% | 0.50% | New | Q3 2025 | |
| $2M | 0.83% | 0.06% | Not reported | Q4 2021 | |
| $910K | 0.38% | 0.11% | -9.1% | Q2 2023 | |
| $626K | 0.26% | 0.94% | New | Q3 2025 | |
| $598K | 0.25% | 0.07% | +16.4% | Q4 2022 | |
| $543K | 0.23% | 0.02% | Not reported | Q4 2023 | |
| $222K | 0.09% | 0.00% | Not reported | Q2 2025 | |
| $177K | 0.07% | 0.02% | Not reported | Q2 2021 | |
| $144K | 0.06% | Not reported | Not reported | Q1 2023 | |
| $92.2K | 0.04% | Not reported | Not reported | Q2 2022 | |
| $33.8K | 0.01% | Not reported | Not reported | Q3 2024 | |
| $11.8K | 0.00% | Not reported | Not reported | Q2 2021 | |
| LPLIMNWLiminatus Pharma, Inc. | $4.32K | 0.00% | Not reported | Not reported | Q2 2025 |
| $2.93K | 0.00% | Not reported | Not reported | Q4 2022 | |
| $1.04K | 0.00% | Not reported | Not reported | Q4 2023 | |
Premium opens every quarter this fund has filed